BiotechTube

Conivaptan

Phase 3Withdrawn
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyponatremia

Conditions

Hyponatremia

Trial Timeline

May 1, 2008 → Jun 1, 2010

NCT ID
NCT00684164

About Conivaptan

Conivaptan is a phase 3 stage product being developed by Astellas Pharma for Hyponatremia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00684164. Target conditions include Hyponatremia.

What happened to similar drugs?

1 of 7 similar drugs in Hyponatremia were approved

Approved (1) Terminated (3) Active (4)
✅ConivaptanAstellas PharmaApproved
🔄YM087Astellas PharmaPhase 3
❌Satavaptan + placeboSanofiPhase 3
🔄lixivaptan + PlaceboBiogenPhase 3
❌LixivaptanBiogenPhase 3
🔄lixivaptan + placeboBiogenPhase 3
🔄Lixivaptan + PlaceboBiogenPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00806910ApprovedWithdrawn
NCT00727090ApprovedTerminated
NCT00684164Phase 3Withdrawn

Competing Products

9 competing products in Hyponatremia

See all competitors
ProductCompanyStageHype Score
YM087Astellas PharmaPhase 3
40
ConivaptanAstellas PharmaApproved
35
Tolvaptan + PlaceboJiangsu Hengrui MedicinePhase 2/3
34
Satavaptan + placeboSanofiPhase 3
32
lixivaptan + PlaceboBiogenPhase 3
37
LixivaptanBiogenPhase 3
29
lixivaptan + placeboBiogenPhase 3
37
Lixivaptan + PlaceboBiogenPhase 3
37
PEG-SD + PEG-ELSBausch HealthPre-clinical
20